Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 3
2(50.0%)
Phase 1
1(25.0%)
Phase 2
1(25.0%)
4Total
Phase 3(2)
Phase 1(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT06842173Phase 1Recruiting

Safety and Immunogenicity of the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented and Adjuvanted) in Adults and Older Adults

Role: collaborator

NCT06891950Phase 3Recruiting

Butantan-DV Vaccine in Elderly Populations (DEN-04-IB)

Role: collaborator

NCT07414524Not Yet Recruiting

VLA1553-403 Pregnancy Surveillance Study

Role: collaborator

NCT07163845Active Not Recruiting

Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil

Role: collaborator

NCT07254702Enrolling By Invitation

Prospective Safety Cohort Study After VLA1553 Vaccination in Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil

Role: collaborator

NCT07347002Enrolling By Invitation

Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Vaccination Strategy in Brazil

Role: collaborator

NCT03927131Phase 3Completed

Safety and Immunogenicity of the Butantan Quadrivalent Influenza Vaccine

Role: collaborator

NCT01696422Phase 2Unknown

Phase II Trial to Evaluate Safety and Immunogenicity of a Dengue 1,2,3,4 (Attenuated) Vaccine

Role: collaborator

All 8 trials loaded